1 in 8
Women will develop invasive breast cancer in their lifetime. Early detection is critical—5-year survival rates drop from 99% (stage 0-1) to 27% (stage 4).
20-30%
Of breast cancers are missed in traditional mammography screenings. AI-enhanced detection can reduce false negatives by up to 9.4% (Nature Medicine, 2023).
43,000+
Women die from breast cancer annually in the US alone. AR-assisted visualization and voice-enabled workflows can accelerate diagnosis by 30%, saving lives.
Why GammaLex & OrenAI
GammaLex is the first to fuse AI, AR, and Voice technologies in breast imaging—a groundbreaking innovation that addresses the critical gap in early cancer detection. Our deep vertical AI expertise in healthcare, combined with cutting-edge multimodal fusion, enables clinicians to detect cancers earlier, reduce false negatives, and improve patient outcomes. OrenAI represents the future of precision diagnostics, where technology amplifies human expertise rather than replacing it.